|
Market Closed -
Euronext Paris
11:55:00 2026-09-03 EDT
|
5-day change | 1st Jan Change | ||
| 0.7780 EUR | -1.14% |
|
-3.59% | +12.10% |
| 07-22 | Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications | CI |
| 06-29 | Valbiotis Raises EUR10 Million for Commercial Development, Working Capital | MT |
Projected Income Statement: Valbiotis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.693 | 2.814 | 6.809 | 4.644 | 1.046 | 3.1 | 12.8 |
| Change | - | 4.49% | 141.97% | -31.8% | -77.48% | 196.37% | 312.9% |
| EBITDA 1 | -7.534 | -11.17 | -6.444 | -9.836 | -9.198 | -7.8 | -2.4 |
| Change | - | -48.31% | 42.33% | -52.64% | 6.49% | 15.2% | 69.23% |
| EBIT 1 | -8.475 | -12.03 | -7.18 | -10.42 | -9.494 | -8 | -2.6 |
| Change | - | -41.9% | 40.3% | -45.17% | 8.91% | 15.74% | 67.5% |
| Interest Paid 1 | -0.206 | -0.227 | -0.188 | -0.23 | 0.058 | -0.2 | -0.2 |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - |
| Net income 1 | -8.681 | -12.31 | -7.368 | -10.02 | -9.417 | -8.2 | -2.8 |
| Change | - | -41.83% | 40.16% | -36.06% | 6.06% | 12.92% | 65.85% |
| Announcement Date | 3/15/22 | 3/15/23 | 4/26/24 | 3/3/25 | 3/2/26 | - | - |
1EUR in Million
Estimates
Forecast Balance Sheet: Valbiotis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | -14.2 | -13.7 | -18.1 | -5.86 | -3.59 | 5.9 | 10.9 |
| Change | - | 3.52% | -32.12% | 67.62% | 38.74% | 264.53% | 84.75% |
| Announcement Date | 3/15/22 | 3/15/23 | 4/26/24 | 3/3/25 | 3/2/26 | - | - |
1EUR in Million
Estimates
Cash Flow Forecast: Valbiotis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| CAPEX 1 | 0.306 | 0.111 | 0.027 | 0.147 | 0.151 | 0.1 | 0.1 |
| Change | - | -63.73% | -75.68% | 444.44% | 2.72% | -33.77% | 0% |
| Free Cash Flow (FCF) 1 | -7.462 | -9.303 | -8.086 | -11.68 | -8.189 | -8 | -5.2 |
| Change | - | -24.67% | 13.08% | -44.5% | 29.91% | 2.31% | 35% |
| Announcement Date | 3/15/22 | 3/15/23 | 4/26/24 | 3/3/25 | 3/2/26 | - | - |
1EUR in Million
Estimates
Forecast Financial Ratios: Valbiotis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | -279.76% | -397.09% | -94.64% | -211.8% | -879.35% | -251.61% | -18.75% |
| EBIT Margin (%) | - | -314.7% | -427.36% | -105.45% | -224.44% | -907.65% | -258.06% | -20.31% |
| EBT Margin (%) | - | - | - | - | - | - | - | - |
| Net margin (%) | - | -322.35% | -437.53% | -108.21% | -215.87% | -900.29% | -264.52% | -21.87% |
| FCF margin (%) | - | -277.09% | -330.6% | -118.75% | -251.59% | -782.89% | -258.06% | -40.62% |
| FCF / Net Income (%) | - | 85.96% | 75.56% | 109.74% | 116.55% | 86.96% | 97.56% | 185.71% |
Profitability | ||||||||
| ROA | -11.78% | -21.18% | -26.87% | -14.79% | -24.63% | -34.91% | - | - |
| ROE | -49.71% | -80.95% | -89.05% | -44.71% | -66.9% | -108.68% | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.76x | -4.54x |
| Debt / Free cash flow | - | - | - | - | - | - | -0.74x | -2.1x |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | 11.36% | 3.94% | 0.4% | 3.17% | 14.44% | 3.23% | 0.78% |
| CAPEX / EBITDA (%) | - | -4.06% | -0.99% | -0.42% | -1.49% | -1.64% | -1.28% | -4.17% |
| CAPEX / FCF (%) | - | -4.1% | -1.19% | -0.33% | -1.26% | -1.84% | -1.25% | -1.92% |
Items per share | ||||||||
| Cash flow per share 1 | - | -0.7814 | -0.9088 | -0.6464 | -0.7305 | -0.4054 | - | - |
| Change | - | - | -16.3% | 28.87% | -13.01% | 44.5% | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | 1.471 | 1.077 | 1.573 | - | - | - | - |
| Change | - | - | -26.8% | 46.09% | - | - | - | - |
| EPS 1 | - | -0.94 | -1.21 | -0.59 | -0.63 | -0.47 | -0.23 | -0.08 |
| Change | - | - | -28.72% | 51.24% | -6.78% | 25.4% | 51.06% | 65.22% |
| Nbr of stocks (in thousands) | - | 9,717 | 12,405 | 12,409 | 15,763 | 23,656 | 23,657 | 23,657 |
| Announcement Date | - | 3/15/22 | 3/15/23 | 4/26/24 | 3/3/25 | 3/2/26 | - | - |
1EUR
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -3.38x | -9.73x |
| PBR | - | - |
| EV / Sales | 7.84x | 2.29x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7780EUR
Average target price
1.800EUR
Spread / Average Target
+131.36%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ALVAL Stock
- Financials Valbiotis
Select your edition
All financial news and data tailored to specific country editions
